Mereo BioPharma Group PLC (MREO) FinancialsMREOMereo BioPharma Group PLC

Evaluating the bottom line, Mereo BioPharma Group PLC maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -67.85%, provide a clear picture of how effectively MREO converts its operational activities into shareholder value.

In the context of the broader market, MREO competes directly with industry leaders such as ELUT and IXHL. With a market capitalization of $44.19M, it holds a leading position in the sector. When comparing efficiency, MREO's gross margin of N/A stands against ELUT's 57.87% and IXHL's N/A. Such benchmarking helps identify whether Mereo BioPharma Group PLC is trading at a premium or discount relative to its financial performance.

Mereo BioPharma reported a gross margin of 73.6% in Q2 2025, but total revenue for the same quarter was only $500,000, indicating limited operational success. The company has consistently reported negative net income, with a net income of -$7,005,000 in Q2 2026.